Page last updated: 2024-11-06

cinitapride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cinitapride is a prokinetic agent that acts as a selective agonist of the 5-HT4 receptor. It is a potent stimulator of gastric emptying and intestinal motility. The compound was first synthesized in the 1980s and was approved for clinical use in Europe in the 1990s. Cinitapride was primarily used to treat gastrointestinal disorders such as dyspepsia, gastroesophageal reflux disease (GERD), and functional dyspepsia. However, it was withdrawn from the market in many countries due to concerns about its potential to prolong the QT interval and increase the risk of cardiac arrhythmias. It is currently under investigation for its potential use in treating other conditions such as irritable bowel syndrome (IBS), constipation, and diabetic gastroparesis. Research into cinitapride focuses on understanding its mechanisms of action, exploring its therapeutic potential in various gastrointestinal disorders, and developing safer and more effective prokinetic agents.'

Cross-References

ID SourceID
PubMed CID68867
CHEMBL ID2104523
CHEBI ID135642
SCHEMBL ID476454
SCHEMBL ID19235643
MeSH IDM0131853

Synonyms (37)

Synonym
cidine
cinitapride hydrogen tartrate
paxapride (tn)
cinitapride (inn)
66564-14-5
D07700
cinitapride
CHEBI:135642
4-amino-n-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
4-amino-n-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide
FT-0665049
BCP9000531
paxapride
CHEMBL2104523
unii-r8i97i2l24
cinitaprida [inn-spanish]
cinitapridum
cinitaprida
r8i97i2l24 ,
cinitapride [inn]
cinitapridum [inn-latin]
BCP0726000107
AKOS015909742
DB08810
SCHEMBL476454
cidin
SCHEMBL19235643
BCP04096
Q5121012
66564-14-5 (free base)
DTXSID60867232
cinitapride [mi]
cinitapride [who-dd]
cinitapride [mart.]
CS-0017505
HY-B2089
AKOS040744830

Research Excerpts

Overview

Cinitapride (CIN) is a benzamide-derived molecule used for the treatment of gastroesophageal reflux and dyspepsia.

ExcerptReferenceRelevance
"Cinitapride (CIN) is a benzamide-derived molecule used for the treatment of gastroesophageal reflux and dyspepsia. "( Development of an UPLC-MS/MS micromethod for quantitation of cinitapride in plasma and its application in a pharmacokinetic interaction trial.
Ángeles, AP; Ávila, Ó; Batista, D; Contreras, L; Esquivel, J; García-González, A; Marcelín-Jiménez, G, 2017
)
2.14

Effects

ExcerptReferenceRelevance
"Cinitapride has been widely given in gastro-esophageal reflux disease (GERD) and dysphagia due to irregularities of GI motilities. "( Stability and in vitro release kinetic studies of cinitapride (1mg) mouth dissolving tablets.
Ahmed, K; Ali, H; Bushra, R; Ghayas, S; Shafiq, Y; Zafar, F, 2019
)
2.21

Actions

ExcerptReferenceRelevance
"Cinitapride had lower risk of total adverse events than domperidone."( Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis.
Li, Y; Liu, H; Qi, Q; Wang, N, 2023
)
1.63

Toxicity

ExcerptReferenceRelevance
" Only one adverse event (sore throat) was reported during the study."( Efficacy and safety of cinitapride in functional dyspepsia.
Baqai, MT; Malik, MN; Ziauddin, F, 2013
)
0.7

Pharmacokinetics

ExcerptReferenceRelevance
"The present clinical trial was designed to evaluate the possible pharmacokinetic and electrocardiographic interactions of the gastroenteric prokinetic drug cinitapride with ketoconazole."( The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole.
Esbri, R; Golor, G; Pavesi, M; Robert, M; Roberts, D; Salvà, M; Segarra, R, 2007
)
0.89
"The method proved to be rapid, accurate and stable within a range between 50 and 2000 pg/ml and was successfully validated and applied in a pharmacokinetic interaction trial, where it was demonstrated that oral co-administration of simethicone does not modify the bioavailability of CIN."( Development of an UPLC-MS/MS micromethod for quantitation of cinitapride in plasma and its application in a pharmacokinetic interaction trial.
Ángeles, AP; Ávila, Ó; Batista, D; Contreras, L; Esquivel, J; García-González, A; Marcelín-Jiménez, G, 2017
)
0.7

Bioavailability

ExcerptReferenceRelevance
"The method proved to be rapid, accurate and stable within a range between 50 and 2000 pg/ml and was successfully validated and applied in a pharmacokinetic interaction trial, where it was demonstrated that oral co-administration of simethicone does not modify the bioavailability of CIN."( Development of an UPLC-MS/MS micromethod for quantitation of cinitapride in plasma and its application in a pharmacokinetic interaction trial.
Ángeles, AP; Ávila, Ó; Batista, D; Contreras, L; Esquivel, J; García-González, A; Marcelín-Jiménez, G, 2017
)
0.7
" MD formulations are actually lessen the difficulties associated with solid swallowing with better bioavailability of especially poorly soluble drugs."( Effects of superdisintegrants in oral dissolving formulation of cinitapride tablets.
Alam, S; Ali, H; Ashfaq, M; Beg, AE; Bushra, R; Mustapha, O; Rehman, A; Shafique, S; Zafar, F, 2018
)
0.72

Dosage Studied

ExcerptRelevanceReference
"A simple stability indicating UV-spectrophotometric method has been developed and validated for the determination of cinitapride hydrogen tartrate (CHT) in bulk and solid pharmaceutical dosage form."( Development and validation of stability indicating assay method for cinitapride in bulk & tablets.
Ali, H; Ashfaq, M; Beg, AE; Bushra, R; Rehman, A; Rizvi, M; Zafar, F, 2017
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (7.69)18.7374
1990's5 (19.23)18.2507
2000's4 (15.38)29.6817
2010's14 (53.85)24.3611
2020's1 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.54 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index126.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (37.93%)5.53%
Reviews2 (6.90%)6.00%
Case Studies5 (17.24%)4.05%
Observational0 (0.00%)0.25%
Other11 (37.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Double-dummy, Active Drug Parallel Controlled, Multi-center Clinical Trial on the Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia [NCT01355276]Phase 3400 participants (Actual)Interventional2010-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]